GNFT · SA GENFIT · Investor Relations

Financial Highlights Cash and cash equivalents totaled €113.8 million as of June 30, 2026; expected to fund the Company beyond the end of 2028 €21.1 million in revenues as of June 30, 2026, including €21.0 million in royalties generated under the Ipsen agreement Key Highlights PBC: Ipsen doubled

GENFIT's acquisition of nangibotide, a differentiated late-stage asset, reinforces the Company’s portfolio of innovative therapies addressing high unmet medical needs The investigation in Phase 2 is supported by a robust scientific and clinical foundation around the TREM-1 pathway and the asset's

Lille (France), Cambridge (Massachusetts, United States), September 11, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that following the annual review of the Euronext Paris

Lille (France), Cambridge (Massachusetts, United States), September 10, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that management will participate in the upcoming H.C.

Simple, reliable and scalable blood-based testing could identify patients with at-risk MASH among nearly 90 million U.S. individuals receiving medical attention due to MASLD-related risk factors IQVIA estimates U.S peak sales of products based on NIS TM Technology could exceed USD 1.5 billion by

Presentations will highlight the clinical utility and long-term commercial opportunity of GENFIT’s proprietary NIS platform, a non-invasive diagnostic technology for MASH Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 3, 2026 - GENFIT (Euronext: GNFT), a

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the half-year report of the liquidity

Coverage and future reimbursement ( effective August 10, 2026) secured for NASHnext®, Labcorp’s non-invasive blood-based diagnostic test powered by GENFIT’s proprietary NIS4® technology Focuses on patients at highest risk, including those with prediabetes, type 2 diabetes, obesity and dyslipidemia

Investigational drug GNS561 showed a favorable safety and tolerability profile in a Phase 1b study evaluating its potential in combination with a MEK inhibitor (MEKi) Study conducted in a heavily pretreated, high - unmet - need population of KRAS - mutated cholangiocarcinoma (CCA) patients who had

All resolutions recommended by the Board of Directors approved (quorum: 32.13%) Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); June 15, 2026 - GENFIT (Euronext: GNFT),, a biopharmaceutical company dedicated to improving the lives of patients with rare and

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population Lille (France),